A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.
研究单位：[1]Peking University Cancer Hospital & Institute[2]Pierre Fabre Medicament[3]Merck KGaA, Darmstadt, Germany[4]Beijing Cancer Hospital,Beijing,Beijing,China,100036[5]Peking Union Medical College Hospital, Chinese Academy of Medical Sciences,Beijing,Beijing,China,100730[6]Fujian Medical University - Fujian Provincial Cancer Hospital,Fuzhou,Fujian,China,350014[7]The First Affiliated Hospital of Xiamen University,Xiamen,Fujian,China,361001[8]The First People's Hospital of Foshan,Foshan,Guangdong,China,528010[9]Cancer Center of Guangzhou Medical University,Guangzhou,Guangdong,China,510095[10]The Sixth Affiliated Hospital Sun Yat-Sen University,Guangzhou,Guangdong,China,510655[11]Cancer Hospital Affiliated to Shantou University Medical College,Shantou,Guangdong,China,515041[12]Peking University Shenzhen Hospital,Shenzhen,Guangdong,China,518036[13]The Affiliated Hospital of Hebei University,Baoding,Hebei,China,071000[14]Harbin Medical University Cancer Hospital,Harbin,Heilongjiang,China,150040[15]Henan Cancer Hospital,Zhengzhou,Henan,China,450008[16]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China,450052[17]Union Hospital Tongji medical college Huazhong University of Science and Technology,Wuhan,Hubei,China,430022[18]Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology,Wuhan,Hubei,China,430030[19]Zhongnan Hospital of Wuhan University,Wuhan,Hubei,China,430071[20]Xiangya Hospital Central South University,Changsha,Hunan,China,410008[21]The First People's Hospital of Changzhou,Changzhou,Jiangsu,China,213003[22]First Affiliated Hospital of Gannan Medical University,Ganzhou,Jiangxi,China,341001[23]The First Affiliated Hospital of Nanchang University,Nanchang,Jiangxi,China,330006[24]The Second Affiliated Hospital of Nanchang University,Nanchang,Jiangxi,China,330006[25]The First Hospital of Jilin University,Changchun,Jilin,China,130021[26]The First Affiliated Hospital of Jinzhou Medical University,Jinzhou,Liaoning,China,121011[27]The First Hospital of China Medical University,Shenyang,Liaoning,China,110001[28]Liaoning Cancer Hospital & Institute,Shenyang,Liaoning,China,110042[29]Shaanxi Provincial People's Hospital,Xi'an,Shaanxi,China,710068[30]Zhongshan Hospital Fudan University,Shanghai,Shanghai,China,200032[31]Huashan Hospital Fudan University,Shanghai,Shanghai,China,200040[32]Xinhua Hospital Affilliated to Shanghai Jiaotong University School of Medicine,Shanghai,Shanghai,China,200092[33]Shanghai East Hospital, Tongji University,Shanghai,Shanghai,China,200120[34]The Second People's Hospital of Neijiang,Neijiang,Sichuan,China,641000[35]Tianjin Medical University Cancer Institute and Hospital,Tianjin,Tianjin,China,300060[36]The First Affiliated Hospital - Zhejiang University School of Medicine,Hangzhou,Zhejiang,China,310003[37]Sir Run Run Shaw Hospital - Zhejiang University School of Medicine,Hangzhou,Zhejiang,China,310016
Encorafenib is currently being developed (with or without binimetinib), in combination with cetuximab, for the treatment of adult patients with B-RAF proto-oncogene, serine/threonine kinase V600E mutant (BRAF V600E) metastatic colorectal cancer (mCRC), who have received prior systemic therapy.
